Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
US Job Growth Seen Picking Up in July 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Asian Stocks Slide as Semiconductor Selloff Weighs on South Korea and Japan 
Oil Prices Slip as Hormuz Shipping Progress and Rising U.S. Crude Stocks Weigh on Market 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
China Exports Beat July Forecasts as AI Demand Fuels High-Tech Trade 
Oil Prices Surge as Iran Hormuz Restrictions Renew Supply Fears 
Asian Currencies Hold Steady as US Dollar Nears Seven-Week Low Ahead of Key Jobs Data 
Asian Currencies Steady as Markets Await U.S. Jobs Data 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
China Trade Surplus Beats Forecasts in July as Exports Stay Strong 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets 
Samsung Biologics just opened the largest Contract Development and Manufacturing Organization (CDMO) plant in the world, and it is located in Incheon, South Korea. The biotech firm is now hoping that through its new pharmaceutical facility, it will be able to replicate the success of its chip manufacturing business.
Samsung Biologics inaugurated the plant on Tuesday, Oct. 11, and it was attended by the vice chairman of Samsung Electronics, Lee Jae Yong. The facility is now the biopharma firm’s fourth factory.
The company usually has an annual production capacity of 240,000 liters and this will now become 420,000 liters as the new plant starts its partial operation. The construction of the Songdo plant began in 2020, and it is expected to go into full operation next year.
As per Korea Joongang Daily, once it runs in full force, Samsung Biologics is expecting to further increase its production capacity up to 620,000 liters. The company said this amount is equivalent to almost 30% of the global contract manufacturing capacity for biopharma firms.
With this volume, Samsung Biologics defeated Switzerland’s Lonza Group AG and Germany's Boehringer Ingelheim pharmaceutical and biotech companies.
In any case, Samsung invested KRW2 trillion or about $1.4 billion for the construction of its new Songdo plant, and in the future, the company may spend a total of KRW7 trillion on building its fifth, sixth, seventh, and eighth plants in the same region but on another site. Samsung Biologics is expanding its facilities to accommodate more orders from its major global clients, such as Pfizer, GlaxoSmithKline, Moderna, Eli Lilly, and AstraZeneca.
Meanwhile, the Samsung chief met with the senior executives of Samsung Biologics and Samsung Bioepis after the inauguration ceremony for the Songdo factory. They talked about mid and long-term strategies to improve competitiveness as CDMO and a biosimilar manufacturer.
The Korea Times reported that at the meeting, Lee Jae Yong vowed to put in a new investment of KRW7.5 trillion or $5.2 billion to widen the gap from its rivals in the bio business and move ahead to become the leader in the industry. He said that Samsung will release the fund for its biotech unit by 2032.
